Top Line: With NRG HN005’s interim results dampening enthusiasm for radiation dose deintensification for HPV mediated oropharyngeal cancer, can long term outcomes from institutional cohorts still defend the approach?
The Study: Deintensification for HPV+ OPC has been attempted through reduced radiation dose, less-toxic systemic therapy, elective volume reduction, transoral surgery with reduced adjuvant therapy (ECOG 3311), and biomarker-adapted approaches. UNC's investigational paradigm for over a decade has been a “modest” deintensification package of 60 Gy in 30 fractions with concurrent weekly cisplatin 30 mg/m² (compared to standard 40 mg/m² weekly or 100 mg/m² q3w). This cohort study reports outcomes for 240 consecutive patients (207 on prospective protocols, 33 off-protocol with similar eligibility) treated between 2014 and 2022, with median follow-up of 6.5 years for survivors. This was a favorable population as all were p16+, only 17% had a >10 pack year smoking history, and only 17% had N2c disease. Most (85.4%) received concurrent chemotherapy, but RT alone was used for those with T0-2 N0-1 disease. The 5-year locoregional recurrence rate was 3.4% (95% CI 1.1–5.8%), distant recurrence 7.3%, PFS 86.5%, and OS 92.4%. Only N2b–N2c disease was significantly associated with worse PFS. Among 33 low-risk patients (T0–T2 N0–N1) treated with RT alone, there were zero locoregional recurrences. A notable long term surveillance finding was that 46% of recurrences occurred after 2 years (median time to progression 1.9 years), arguing strongly against truncating long-term follow-up even in this low risk population.
TBL: These mature nonrandomized institutional results are reassuring on their own terms, but they sit uncomfortably alongside NRG-HN005's interim results where both 60 Gy experimental arms failed noninferiority and the trial did not proceed to phase 3. 70 Gy with concurrent cisplatin remains the off trial standard in HPV mediated oropharyngeal cancer. | Morse, JAMA Otolaryngo Head Neck Surg 2026
The Study: Deintensification for HPV+ OPC has been attempted through reduced radiation dose, less-toxic systemic therapy, elective volume reduction, transoral surgery with reduced adjuvant therapy (ECOG 3311), and biomarker-adapted approaches. UNC's investigational paradigm for over a decade has been a “modest” deintensification package of 60 Gy in 30 fractions with concurrent weekly cisplatin 30 mg/m² (compared to standard 40 mg/m² weekly or 100 mg/m² q3w). This cohort study reports outcomes for 240 consecutive patients (207 on prospective protocols, 33 off-protocol with similar eligibility) treated between 2014 and 2022, with median follow-up of 6.5 years for survivors. This was a favorable population as all were p16+, only 17% had a >10 pack year smoking history, and only 17% had N2c disease. Most (85.4%) received concurrent chemotherapy, but RT alone was used for those with T0-2 N0-1 disease. The 5-year locoregional recurrence rate was 3.4% (95% CI 1.1–5.8%), distant recurrence 7.3%, PFS 86.5%, and OS 92.4%. Only N2b–N2c disease was significantly associated with worse PFS. Among 33 low-risk patients (T0–T2 N0–N1) treated with RT alone, there were zero locoregional recurrences. A notable long term surveillance finding was that 46% of recurrences occurred after 2 years (median time to progression 1.9 years), arguing strongly against truncating long-term follow-up even in this low risk population.
TBL: These mature nonrandomized institutional results are reassuring on their own terms, but they sit uncomfortably alongside NRG-HN005's interim results where both 60 Gy experimental arms failed noninferiority and the trial did not proceed to phase 3. 70 Gy with concurrent cisplatin remains the off trial standard in HPV mediated oropharyngeal cancer. | Morse, JAMA Otolaryngo Head Neck Surg 2026